Fate Therapeutics Inc financial data

Symbol
FATE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
12278 Scripps Summit Drive, San Diego, California
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 869 % +50.1%
Return On Equity -46.5 % -1.93%
Return On Assets -34.5 % -6.13%
Operating Margin -3.29K % -1614%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 114M shares +15.7%
Common Stock, Shares, Outstanding 114M shares +15.9%
Common Stock, Value, Issued 114K USD +16.3%
Weighted Average Number of Shares Outstanding, Basic 101M shares +3.11%
Weighted Average Number of Shares Outstanding, Diluted 101M shares +3.11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.48M USD -95.3%
Research and Development Expense 139M USD -55.7%
General and Administrative Expense 80.4M USD -5.94%
Operating Income (Loss) -213M USD +18.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -190M USD +19.1%
Earnings Per Share, Basic -1.92 USD/shares +20.7%
Earnings Per Share, Diluted -1.92 USD/shares +20.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 121M USD +189%
Accounts Receivable, after Allowance for Credit Loss, Current 858K USD -93.6%
Assets, Current 394M USD -9.94%
Property, Plant and Equipment, Net 92.1M USD -15.2%
Operating Lease, Right-of-Use Asset 60.6M USD -6.28%
Other Assets, Noncurrent 9K USD -72.7%
Assets 570M USD -9.59%
Accounts Payable, Current 6.77M USD -31.4%
Accrued Liabilities, Current 32M USD +1.68%
Contract with Customer, Liability, Current 159K USD -90.9%
Liabilities, Current 45.4M USD -6.75%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 95.7M USD -6.27%
Accumulated Other Comprehensive Income (Loss), Net of Tax -194K USD +70%
Retained Earnings (Accumulated Deficit) -1.26B USD -17.8%
Stockholders' Equity Attributable to Parent 426M USD -10.8%
Liabilities and Equity 570M USD -9.59%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.4M USD -15.6%
Net Cash Provided by (Used in) Financing Activities 95.5M USD +46029%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +85.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 114M shares +15.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 79.5M USD
Deferred Tax Assets, Valuation Allowance 324M USD +9.36%
Deferred Tax Assets, Gross 343M USD +8.11%
Operating Lease, Liability 102M USD -5.15%
Payments to Acquire Property, Plant, and Equipment 86K USD -97.3%
Lessee, Operating Lease, Liability, to be Paid 159M USD -8.28%
Property, Plant and Equipment, Gross 144M USD +2.89%
Operating Lease, Liability, Current 6.4M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.5M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.1M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57.2M USD -13.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +33.3%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 59.7M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.1M USD -5.93%
Additional Paid in Capital 1.69B USD +8.93%
Depreciation, Depletion and Amortization 4.82M USD +15%
Share-based Payment Arrangement, Expense 43.5M USD -38.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%